Generics to drive down HIV drug sales in next decade

Study finds uptake of newer therapies like single-tablet regimens to drive sales

BURLINGTON, Mass. — The availability of new generic drugs for treating HIV will erode sales of HIV antiretroviral drugs into the next decade in developed countries, according to a new report.

Healthcare market research firm Decision Resources released the report Wednesday, showing that sales of antiretroviral drugs in the United States, France, Germany, the United Kingdom, Spain, Italy and Japan would be $13.1 billion in 2022, down from 2012's $13.4 billion.

Meanwhile, such single-tablet regimens as Atripla (efavirenz; emtricitabine; tenofovir) from Gilead Sciences and Bristol-Myers Squibb will drive sales in the future.

 

Login or Register to post a comment.